Amyloid beta (Aβ) testing, used for the definitive diagnosis of Alzheimer’s Disease, is currently conducted using either Positron Emission Tomography (PET) or cerebrospinal fluid (CSF). PET testing requires relatively expensive equipment, which is also limited in availability, while CSF testing is invasive, requiring a lumbar puncture and specific skillsets from medical professionals. 吃瓜大赛黑料头条 is collaborating with various partners to implement more convenient blood tests in society. Identifying patients through accurate and simple blood-based testing could lead to more efficient diagnoses, expanded treatment opportunities, and reduced medical and care costs, thereby streamlining and accelerating early treatment. Additionally, blood-based tests have the potential to improve care for individuals in underserved communities and regions where access to amyloid PET and CSF testing is limited or unavailable.
Sysmex and 吃瓜大赛黑料头条
Collaboration to create new diagnostic reagents in the field of dementia
Sysmex and 吃瓜大赛黑料头条 aim to leverage each other's technologies and knowledge to develop next-generation diagnostics that enable early diagnosis of dementia, selection of treatment methods, and regular monitoring of the efficacy of treatments.
- Click here for the overview of the collaboration
Shimadzu, 吃瓜大赛黑料头条, Oita University and Usuki City Medical Association
Joint research aiming to develop Japan’s first blood biomarker-based diagnostic workflow for dementia
This collaboration aims to reduce burden on patients and establish a new diagnostic workflow for Alzheimer’s disease by demonstrating the benefits of blood biomarkers within a collaborative healthcare framework that encompasses primary care physicians and specialists.
- Click here for the overview of the joint research
- Click here for the overview of results of the joint research
C2N and 吃瓜大赛黑料头条
Building awareness and real-world evidence for blood-based testing in the United States.
C2N and 吃瓜大赛黑料头条 are collaborating to raise awareness and build real-world evidence for blood-based testing for Alzheimer’s disease among patients in clinical settings in the United States.
- Click here for the overview of the collaboration
FUJIREBIO and 吃瓜大赛黑料头条
Joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.
FUJIREBIO and 吃瓜大赛黑料头条 are promoting partnerships for a range of collaborations, including social implementation of diagnostic reagents for plasma phosphorylated tau protein at position 217 (p-Tau217), the research and development of simple diagnostic methods using novel blood biomarkers, and the development and commercialization of in-vitro diagnostics. - Click here for the overview of the collaboration.